The information in this section is intended exclusively for HCPs in Europe.
By checking the box you confirm you are a licensed HCP and understand that cenobamate is not approved in Europe.
Welcome to Arvelle’s Medical Information Services
Our mission is to provide you with accurate, timely, tailor-based, balanced scientific information to answer your medical information requests. You can also use this webpage to report any adverse event or product complaint.
To view our Early Access Programme Policy, please click on the link below
To report an adverse event or a product quality complaint, or for medical information, please call:
Focal onset seizures (FOS) account for over 60% of all epilepsy cases.4
FOS are more often uncontrolled compared to patients with generalised seizures.5 Even with significant therapy advancements, overall treatment outcomes have not significantly improved in the past 20 years.1, 6 Many patients with drug-resistant FOS do not reach seizure freedom, despite trying two or more ASMs.1
Is it any wonder that treatment goals are often reassessed?
* Experiencing at least one seizure in the past five years compared with those who were seizure free for five years.7
** Incidence rate ratio 9.3–13.4.8
Uncontrolled seizures have additional psychosocial implications.
Patients with uncontrolled seizures are:7
- 2x as likely to experience stigma in their daily lives.
- 4.5x more likely to be prevented from driving.
- 3x more likely to have restrictions in employment.
- 2x as likely to have limited education.
Assess your treatment goals. As your patients persevere, so do you.
What is the path to achieving seizure freedom?*
What is the most effective way to reduce seizure frequency?
How can we reduce seizure severity?**
How can we minimise side effects?
* Defined as being free from seizures for 12 months or longer.1
** Defined as seizure type.
The treatment goal in epilepsy therapy should be the reduction of seizure frequency and severity and, eventually, achieving seizure freedom.9, 10, 11